By: Baystreet Staff - Monday, February 02, 2015 Cannabix Technologies Provides Progress Update on its Marijuana Breathalyzer [ACCESSWIRE] The Cannabix Hand-held Marijuana Breathalyzer is being developed to give law enforcement and employers the ability to test for recent consumption of the THC component of marijuana. Vancouver, British Columbia / ACCESSWIRE / February 2, 2015 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF), developer of the patent-pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that the development of its marijuana breathalyzer prototype is proceeding as planned with the mechanical design, circuit board layouts, firmware, and printed circuit board designs all nearing completion. Cannabix is developing a feature rich, durable, hand-held marijuana breathalyzer device for law enforcement and the workplace. "We expect our prototype to be complete in the coming weeks and we'll be sharing news about testing," said Kal Malhi, President of Cannabix Technologies Inc. "Our team is working hard to deliver a prototype for trial testing as quickly as possible." The Company also reports that Dr. Raj Attariwala, MD, PhD, will be joining the Cannabix Board of Directors, subject to ratification at the AGM and special meeting to be held in February, 2015. Dr. Attariwala is a Vancouver based dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He holds a doctorate in Biomedical Engineering from Northwestern University. Dr. Attariwala is Cannabix's lead product development engineer and has utilized his educational training and background in biomedical engineering to formulate product design and patent applications for Cannabix breathalyzer products. For more information and to sign up for email updates please visit cannabixtechnologies.com. About Cannabix Technologies Inc. Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. The device is currently in prototype development and the Company is rapidly developing this technology. We seek Safe Harbor. On behalf of the Board of Directors "Rav Mlait" CEO Cannabix Technologies Inc. For further information, contact the Company's CEO, Rav Mlait 604-551-7831 email at firstname.lastname@example.org The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.SOURCE: Cannabix Technologies Inc.